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Abstract
Background: The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) research program aims to defeat
the rising HIV epidemic among adolescents and young adults in the United States.
Objective: This study aims to optimize cross-study analyses and comparisons of standardized measures (variables) collected
in the ATN.
Methods: Guidelines were developed for harmonizing measures to be collected across ATN studies.
Results: Eight domains were identified for harmonization—Demographics and Socioeconomic Characteristics, Sexual Behavior
and Risk, Substance Use and Abuse, HIV-Positive Cascade, HIV-Negative Cascade, Mental Health, Social Support and Isolation,
and Pre-exposure Prophylaxis Cascade.
Conclusions: The collection of selected key measures in a uniform manner across studies facilitates the characterization of
participant populations, comparisons between studies, and pooled analysis of data from multiple studies.
(JMIR Res Protoc 2018;7(12):e11207)   doi:10.2196/11207
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Introduction
The Adolescent Medicine Trials Network for HIV/AIDS
Interventions (ATN) research program aims to defeat the rising
HIV epidemic among adolescents and young adults in the United
States by increasing awareness of the HIV status and access to
health care for those diagnosed with HIV. The ATN develops
and conducts behavioral, community-based, translational,
therapeutic, microbicide, and vaccine trials in HIV-at-risk and
HIV-infected youth aged 12-24 years, with a focus on the
inclusion of minors. The ATN research is conducted through
collaborations within the network and with researchers in other
institutions across the United States. The ATN website [1]
provides additional information about the network.
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The ATN currently includes 3 research program projects (or
U19s) and a Coordinating Center with >20 currently active
study protocols across the network. Without standardization,
data collected across these different studies may be difficult or
impossible to combine. In turn, this could potentially hamper
efforts to compare data across studies or describe the US
adolescent and youth populations choosing to participate in the
ATN research.
Therefore, the ATN Analytic Committee (AC) developed
guidelines for harmonizing (ie, standardizing) measures
(variables) to be collected across ATN studies to optimize
cross-study analyses and comparisons. This set of harmonized
measures facilitates pooled analysis of data and allows the
characterization and comparison of participants across ATN
studies conducted among diverse populations in the United
States.
Methods
Adolescent Medicine Trials Network for HIV/AIDS
Interventions Data Harmonization Process
The AC developed a set of harmonized measures to be collected
across the diverse set of projects in the ATN. Eight domains
were identified for harmonization: 5 “standard” domains for
which characteristics (measures, variables) will be collected in
all ATN studies unless a strong operational or scientific rationale
exists otherwise; and 3 “additional” domains for studies planning
to collect data in these domains (Figure 1). The data
harmonization guidelines focus primarily on survey questions
and measures and include recommendations for the order in
which the measures should be collected, as well as the ordering
of levels for particular measures.
The 5 standard domains were developed by reviewing common
measures collected by previous and current ATN studies and
identifying key areas of interest among ATN studies; these
domains included “Demographics and Socioeconomic
Characteristics,” “Sexual Behavior and Risk,” “Substance Use
and Abuse,” “HIV-Negative Cascade,” and “HIV-Positive
Cascade.” The 3 additional measure domains that were identified
for harmonization across ATN studies included “Mental Health,”
“Social Support and Isolation,” and the “Motivational
Pre-exposure Prophylaxis (PrEP) Cascade.” These additional
measures are not required but recommended for studies that
plan to collect related information. The ATN data harmonization
guidelines were reviewed and received the final approval by
the ATN Executive Committee (EC). The following paragraphs
describe the process undertaken by the ATN AC for identifying
and selecting measures to include within each domain before
submission to the ATN EC for approval.
Standard Domains
The “Demographics and Socioeconomic Characteristics” domain
was developed by the collective AC by compiling common
survey questions and measures collected in current and previous
ATN studies. A draft of the demographic and socioeconomic
measures was then distributed to AC members for discussion.
The AC members provided their feedback and measures were
discussed during biweekly calls. The AC removed measures
from the standard domains that could not obtain AC and EC
consensus, but these measures remain available for optional use
by future ATN studies.
The AC identified “Substance Use and Abuse,” “Sexual
Behavior and Risk,” “HIV-Negative Cascade,” and
“HIV-Positive Cascade” as critical domains to be developed by
smaller working groups. To facilitate the creation of working
groups for each of these 4 domains, U19 team members
indicated their willingness to participate in or lead any of the 4
working groups. These working groups were charged with 3
objectives as follows: (1) review currently planned and
previously conducted ATN studies to gain a broad understanding
of data points within the domain that might be collected in future
ATN research studies; (2) evaluate potential data items for the
utility and feasibility of collection in a standardized manner in
upcoming ATN research studies; and (3) recommend a core set
of data items for collection in upcoming ATN studies and
provide additional recommendations that might be used in some
but not all studies, if appropriate. The working groups held calls
as needed to review the existing measures and literature and
develop a list of proposed questions and measures to include in
their assigned domain. The recommended questions and
measures were then presented to the larger AC for feedback
and approval.
The Sexual Activity and Other Risk Behaviors Working Group
sought to determine a minimum number of data points with
broad relevance by utilizing data measures from the Youth Risk
Behavior Surveillance (YRBS) [2,3].
Prior to the formation of the working groups, the AC agreed
that using the Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST) would be a good starting place for
the “Substance Use and Abuse” domain [4]; this decision was
largely based on the use of the ASSIST instrument in previous
ATN studies. The Substance Use and Abuse Working Group
then identified additional variables that are often included in
ATN studies’ data collection instruments but are not already
collected in the ASSIST.
The “HIV-Negative Cascade” and “HIV-Positive Cascade”
domains are critical components to the data harmonization
guidelines because the ATN research agenda is focused on the
prevention and treatment care continua. Regarding the HIV
prevention cascade, the ATN seeks to develop and examine the
feasibility and potential impact of the delivery of novel services,
delivery of services in novel settings, and the use of novel
engagement strategies for reaching high-risk youth and
promoting the uptake of essential services such as HIV testing,
sexually transmitted infections (STI) testing, risk screening,
condom distribution, PrEP, and postexposure prophylaxis (PEP).
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Figure 1. A summary of the domains included in the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) data harmonization
guidelines. GAD: Generalized Anxiety Disorder; NHBS: National HIV Behavioral Surveillance System; PHQ: Patient Health Questionnaire.
For the HIV treatment and care cascade, the ATN seeks to
determine the most effective strategy or set of strategies for
linking positive youth to care, promoting retention in care
(including antiretroviral uptake and adherence), and obtaining
and sustaining viral suppression. These research goals motivated
the selection of many of the measures included in the
“HIV-Negative Cascade” and “HIV-Positive Cascade” domains,
as well as in other standard domains. The HIV-Negative Cascade
and HIV-Positive Cascade Working Groups used measures from
existing surveys, like the National HIV Behavioral Surveillance
(NHBS) survey [5], and some additional customized data items
used in previous ATN studies to define a minimum set of
harmonized measures that would capture information along the
continua.
Additional Domains
For the 3 additional domains for harmonization (Mental Health,
Social Support and Isolation, and Motivational PrEP Cascade),
the process was streamlined. U19 representatives proposed sets
of measures that were already harmonized within their U19.
The Patient Health Questionnaire and the Generalized Anxiety
Disorder Scale (GAD) were proposed to measure mental health
[6-10], while the Patient-Reported Outcomes Measurement
Information System (PROMIS) measures were proposed to
measure social support and social isolation [11]. The
Motivational PrEP Cascade measures were adapted for use with
adolescents from measures developed by the Center for HIV
Educational Studies & Training at Hunter College for use in
HIV-negative men who have sex with men (MSM) [12]. The
AC reviewed and approved the compiled measures before
receiving the final approval from the ATN EC.
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Adolescent Medicine Trials Network for HIV/AIDS
Interventions Data Harmonization Guidelines
The ATN data harmonization guidelines describe general
guidelines in addition to domain-specific harmonizing measures
or variables to be collected across ongoing and upcoming ATN
studies (Multimedia Appendix 1). These guidelines provide
specific formatting and skip pattern information for
standardization across the ATN. Standardized data fields and
datasets are critical to enabling comparisons across studies and
analyses that combine data from multiple network studies.
The general data harmonization guidelines are as follows:
1. For the 5 standard domains, all characteristics (measures,
variables) should be collected in all ATN studies, except
when there is a strong operational or scientific rationale to
exclude them. Measures for the 3 additional domains
(Mental Health, Social Support and Isolation, and the
Motivational PrEP Cascade) are recommended for studies
planning to collect data in these domains.
2. Conventions for nonresponse will be handled on a per study
basis. Thus, where relevant, the set of acceptable values
(levels or responses) for a given variable may be augmented
with additional values such as “Don’t know” or “Unsure.”
Individual study teams are encouraged to develop data
collection strategies that minimize nonresponse or missing
data.
3. In general, the order of characteristics does not reflect any
suggested ordering for data collection, unless indicated
otherwise. For example, the current National Institute of
Health (NIH) and Food and Drug Administration guideline
recommends a 2-question format for requesting race and
ethnicity information, with the ethnicity question preceding
the question about race.
4. For a particular characteristic, the following is
recommended regarding the ordering of the levels (possible
responses). First, following Clinical Data Acquisition
Standards Harmonization recommendations, a consistent
order of responses should be used from question to question;
exceptions to this would be cases where a validated
instrument (eg, a standardized assessment questionnaire)
is used. If there is a logical sequential order (ie, ordinal
variables), as in the current educational level, order the
levels accordingly. For nonordinal variables, order
according to the anticipated likelihood of response level or
alphabetically.
5. Possible response values can be separated further, if finer
details are desired. However, more detailed possible
response values should be designed in a way that they can
be aggregated to match the values listed for each of the
harmonized data items in Multimedia Appendix 1.
6. Skip patterns are highlighted in blue within the data
harmonization tables provided in Multimedia Appendix 1.
Standard Domains
Demographic and Socioeconomic Characteristics
The initial data domain selected for ATN-wide harmonization
included demographic characteristics, socioeconomic status
characteristics, and characteristics of participant sexuality (Table
1 in Multimedia Appendix 1). These characteristics were
identified to be of primary importance owing to their relevance
to virtually all ATN studies and the desire of the ATN to be
able to characterize the adolescent populations recruited by the
ATN using consistently collected data elements. Race and
ethnicity data were collected in accordance with the current
Food and Drug Administration guidelines and NIH policy
[13,14]; in accordance with that policy, ethnicity data were
solicited first, and the race was collected in a
check-all-that-apply format. The ZIP code for the location at
which each participant primarily lives was collected to allow
linkage to census track data. In addition, data on each
participant’s current gender identity, sex assigned at birth, and
sexual identity were collected. The possible responses to these
questions were designed to be consistent with the National
Coalition for Sexual Health guidelines for health care providers
and customized for adolescent populations served by the ATN
[15]. Owing to the significant footprint of the ATN in the
Lesbian, Gay, Bisexual, Transgender, Queer adolescent
community, we collected several data elements regarding the
degree to which immediate family members and peers are aware
of participants’ sexual identity. A supportive family environment
has been shown to be highly influential regarding a Lesbian,
Gay, Bisexual, Transgender, Queer adolescent’s mental and
physical health and risk-taking behavior [16-18]. Furthermore,
data elements related to whether a participant is currently in
school or working, their level of education, and their health
insurance coverage were collected to characterize the
socioeconomic status.
Sexual Behavior and Risk
The Sexual Behavior and Risk domain aims to evaluate the
occurrence of sexual behavior and sexual HIV transmission risk
among the general ATN study populations. The content selection
was informed by data from the YRBS, which identified low
rates of condom use, a high number of sexual partners, and
concurrent substance use during sex among the challenges to
HIV prevention among youth [2]. To maximize comparability
to existing national datasets on sexual behavior among youth,
the working group included members who were familiar with
the implementation of sexual behavior measures utilized in the
YRBS. Wherever possible, ATN-harmonized questions were
designed to be comparable to YRBS. It is recommended that
the characteristics listed be collected in the order presented in
Table 2 of Multimedia Appendix 1.
To reduce participant demand, the working group opted to
collect count-data on the number of sexual partners (lifetime
and past 3 months) but not on the number of sexual events.
Because questions on the biomedical prevention uptake were
developed as part of the HIV-Negative Cascade, this domain
focused on the assessment of condom use during sex. Again,
to minimize the participants’ burden, the decision was made to
prioritize identifying the mere occurrence of recent (past 3
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month) condomless sex rather than quantifying the amount of
risk (eg, the number of condomless sex events). To do this, a
series of “yes“ or ”no” questions asking about condomless sex
with partners whose HIV status was known (either HIV-negative
or HIV-positive) or unknown were included in the harmonized
measures. In lieu of collecting data on the number of condomless
sex acts, a visual analog scale was utilized to query the
percentage of time participants utilized condoms while having
sex in the past 3 months. Finally, the working group incorporated
a single item inquiring about the lifetime occurrence of either
alcohol or drug use during vaginal or anal sex.
The working group acknowledges that the harmonized sexual
behavior and risk measures are limited in their nature. Studies
within the ATN vary in their emphasis on sex; thus, nuanced
data on sexual behavior would represent an unnecessary burden
on participants in some studies. In contrast, studies aimed at
achieving reductions in the sexual HIV transmission risk may
need substantially more detail in their data collection. For these
studies, the working group recommended the AIDS Behavior
Risk Assessment, the YRBS, or the NHBS questionnaire as
additional resources [2,5,19-21].
Substance Use and Abuse
Many adolescents experiment with the use of alcohol or other
illicit substances [22,23]. The use of such substances has been
shown to be associated with an increase in risky sexual behavior
and, therefore, a greater risk for HIV transmission [24-26]. The
ATN adapted several standardized instruments to assess alcohol
and nonprescription drug use for use in studies of adolescents
(Table 3 in Multimedia Appendix 1). The ATN data collection
instrument was primarily derived from the ASSIST [4,27,28],
which has been used in previous ATN studies (eg, ATN 071).
As its name suggests, the ASSIST is a screening tool for
substance use to be used in a clinical setting. For the ATN, it
was adapted for computer-assisted self-interview as a means of
quantifying the degree of substance use for adolescent
participants and to collect basic information on the impact of
substance abuse on their daily lives. In ATN studies where site
staff will administer the ASSIST, the Substance Use and Abuse
Working Group recommended using the traditional,
interviewer-administered ASSIST format, which is designed
for that type of implementation [23].
Substance use was assessed for the following classes of
substances: tobacco, alcohol, cannabis, cocaine, amphetamines,
inhalants, sedatives, hallucinogens, and opioids. For most
substances, ≥5 examples were given using terminology
appropriate for the adolescent populations studied by the ATN
(eg, Vicodin instead of acetaminophen-hydrocodone).
Explanatory prompts were added owing to the self-interview
format required for most ATN studies. The data collection on
opioid use was augmented by the addition of 2 questions
regarding the specific use of heroin during the current epidemic
in the United States [29]. The data collection on alcohol use
was augmented by the addition of 2 questions derived from the
Alcohol Use Disorders Identification Test (AUDIT-C) to assess
binge drinking owing to its prevalence in adolescent populations
[29,30]. The definition of binge drinking used for the data
collection was taken from the National Institute of Alcohol
Abuse and Alcoholism [31].
For each class of substance, the harmonized measures assess
the lifetime use (item 1) and aspects of usage over the past 3
months (items 2-5). Per the recommendation of the Substance
Use and Abuse Working Group, ATN studies can also collect
data on the aspects of usage using a frame of reference of the
past 12 months to better align with the NHBS study, if desired.
Substance use data are collected by the ATN for 2 purposes as
follows: (1) to quantify the prevalence of substance in the
populations studied; and (2) to facilitate risk adjustment in
analyses that are more central to ATN research aims. The
ASSIST provides an appealing solution for the second purpose.
Each question on the ASSIST has a set of responses to choose
from, and each response from questions 2-7 has a numerical
score. The scores from questions 2-7 are added across each
substance (eg, tobacco, alcohol, or cannabis) to produce an
ASSIST risk score for each substance. In technical reports and
papers, this score was referred to as the specific substance
involvement score for each drug class. More details on scoring
can be found in the ASSIST manual [4]. The translation of
individual survey responses to a summary risk score is appealing
for the ATN as this provides a standardized framework for
performing risk adjustment for relevant analyses in ATN studies.
In contrast, survey items from large national surveys, such as
Monitoring the Future [22,23,32], assess substance use for the
primary purpose of characterizing the prevalence of use in US
adolescents and, therefore, may be less useful for research aims
that are of primary importance to the ATN.
HIV-Negative Cascade
The HIV-Negative Cascade focuses on the prevention of HIV
among adolescents and includes measures related to HIV testing,
STI testing, PEP and PrEP awareness, utilization, adherence,
and barriers to PrEP utilization and adherence (Table 4 in
Multimedia Appendix 1). General HIV testing and STI questions
for the HIV-Negative Cascade were taken from the NHBS
questionnaire. The Centers for Disease Control and Prevention
(CDC), in collaboration with 25 state and local health
departments, began the NHBS in 2003. The NHBS was designed
to conduct behavioral surveillance among persons at high risk
for HIV infection and surveyed the 3 populations at highest risk
for HIV in the United States—MSM, intravenous drug use, and
high-risk heterosexuals [20,33]. PEP and PrEP awareness and
utilization questions were taken from the University of
California at San Francisco HIV risk assessment tool, NHBS
[5], and assessments used in the ATN’s Scale It Up [12] and
CARES studies.
For studies planning to collect more detailed information related
to PrEP, the AC recommended harmonized measures from the
Motivational PrEP Cascade as additional measures (Table 9 in
Multimedia Appendix 1). The NHBS instrument might also be
considered for studies that will collect measures related to the
HIV-Negative Cascade at a more detailed level than the required
harmonized measures [5]. This questionnaire makes extensive
use of skip patterns to ask questions specific to gender identity
and sexual orientation. The NHBS data provide behavioral
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context trends in HIV surveillance data and describe populations
in the United States at increased risk for HIV infection.
HIV-Positive Cascade
This domain was developed with the goal of identifying key
characteristics among HIV-infected participants that correspond
to steps along the HIV Continuum of Care, using common
definitions developed by the Health Resources and Services
Administration HIV/AIDS Bureau and the CDC. The steps in
the continuum are typically defined using biomedical data
collected during clinical care for HIV-infected patients,
including the CD4 count and HIV viral load before and after
initiation of antiretroviral therapy (ART). Linkage to care, for
example, is defined as having ≥1 documented CD4 or viral load
measures within 30 days (1 month) of diagnosis, while retention
is defined as having ≥2 viral load or CD4 tests in the last year,
performed, at least, 3 months apart.
The participant questions in this domain primarily address
medical appointments with HIV providers, missed visits, CD4
and viral load testing, and adherence to ART, using questions
derived from several sources, including the NHBS and prior
ATN studies (Tables 5 and 6 in Multimedia Appendix 1). In
addition, the HIV-Positive Cascade Working Group developed
4 additional questions for data harmonization that capture
participants’ characteristics corresponding to reengagement and
retention in care based on missed appointments over time.
Furthermore, the NHBS survey instrument might be considered
for studies that will collect measures related to the HIV-Positive
Cascade at a more detailed level than the required harmonized
measures [5]. For studies collecting CD4 count from biomedical
data, it is recommended that investigators collect the CD4
collection date, CD4+ T-cell absolute count (cells/mm3), CD4-
T-cell percent (%), and data source (similar to Viral Load Data
Source; Table 6 in Multimedia Appendix 1).
Additional Domains
Mental Health
In the United States, anxiety and depression are among the most
common mental health disorders for adolescents and young
adults [34]. For HIV-positive youth, anxiety and depression
have been associated with poorer medication adherence and
decreased viral suppression [35-40]. Furthermore, direct and
indirect relationships between depression and anxiety and
increased sexual risk behaviors among youth have been
identified in several studies [41], though other studies have
found null or conflicting findings.
The Mental Health domain collects data on anxiety and
depression using a 2-step approach. All study participants
complete the 2-item Patient Hospital Questionnaire (PHQ-2)
and the 2-item Generalized Anxiety Disorder Scale (GAD-2),
which are used to screen for depression and anxiety,
respectively. The PHQ-2 consists of the first 2 items of the
8-item version of the questionnaire, the PHQ-8, and assesses
the 2 core criteria for depressive disorders. The PHQ-2 has good
operating characteristics (eg, sensitivity and specificity) for
detecting depressive disorders [6,7]. The GAD-2 includes the
first 2 items of the 7-item version of the scale, the GAD-7, and
assesses the 2 core criteria for generalized anxiety disorder. In
addition, the GAD-2 items have been found to be appropriate
screening items for panic, social anxiety, and posttraumatic
stress disorders. The GAD-2 has good operating characteristics
for screening for all 4 types of anxiety disorders [7,8]. For study
participants who screen positive on the PHQ-2 or GAD-2, the
remaining items of the PHQ-8 or GAD-7 are administered to
determine the symptom severity (described in Table 7 of
Multimedia Appendix 1). Furthermore, the longer PHQ-8 and
GAD-7 with broader scoring ranges may be useful for examining
changes in depression and anxiety over time. Both the PHQ-8
and the GAD-7 have been shown to be reliable and valid
measures [7-10].
Social Support and Isolation
The Social Support and Isolation domain uses the PROMIS
short-form versions of the Social Relationships scales to measure
perceived social isolation and social support [42]. PROMIS, an
NIH initiative, uses rigorous processes to develop and test item
banks that measure physical, mental, and social health
components [11]. The 5 Social Relationships short-form scales,
each with 4 items, measure domains of social isolation and
social support, including companionship, emotional support,
informational support, and instrumental support [42]. The Social
Support and Isolation measures are included in Table 8 of
Multimedia Appendix 1.
Motivational Pre-exposure Prophylaxis Cascade
The Motivational PrEP Cascade domain and measurements
utilize the Transtheoretical Model of Change framework to
assess the psychological stages HIV-negative individuals
determine their willingness, intentions, uptake, and adherence
to PrEP [43]. The development of the Motivational PrEP
Cascade was based on the formative work suggesting that,
among individuals willing to take PrEP (ie, those for whom
PrEP acceptability is high), there was wide variability in
behavioral intentions to do so [44]. The Motivational PrEP
Cascade complements the HIV-Negative and HIV-Positive
Cascades with the overall goal of identifying facilitators and
barriers to the PrEP uptake needed for addressing
implementation issues. The measurements have been tested on
a national sample of HIV-negative gay and bisexual men in the
United States with results identifying fewer than 1 in 10 as
currently using and adhering to PrEP [12]. Based on this initial
work, questions were adapted for youth and a reduced 15-item
version of the scale containing only questions considered
essential to estimating progress along the PrEP Cascade was
selected for inclusion in the harmonized ATN measures (Table
9 in Multimedia Appendix 1).
There are 5 stages to the Motivational PrEP Cascade that reflect
decision-making processes across time. The cascade is most
appropriate for samples of objectively identified PrEP candidates
based on the risk for HIV infection using the established CDC
criteria [45]. The inclusion of individuals into the cascade who
are not at risk for HIV infection may confound accurate
prevention numbers. Stage 1 is PrEP precontemplation and
includes individuals who are objectively identified as PrEP
candidates, but do not view themselves as good candidates for
PrEP or are unwilling to pursue PrEP. Those who do not meet
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the criteria for stage 2 are considered PrEP precontemplation.
Stage 2: PrEP contemplation includes those who identify
themselves as PrEP candidates (Table 9: PrEP_Q1) and willing
to pursue PrEP. Willingness was defined as those indicating
they would probably or definitely take PrEP if they could get
it for free and without their parent’s knowing (Table 9: PrEP_Q6
and PrEP_Q7). Stage 3: Preparation includes those who intend
to start PrEP but have not yet started (Table 9: PrEP_Q8) and
who know of a medical provider that would prescribe PrEP
(Table 9: PrEP_Q10). Those indicating they would definitely
or probably start taking PrEP were coded as intending to begin
PrEP. Those who had talked to a medical provider about starting
PrEP and both thought they should start PrEP (Table 9:
PrEP_Q11) and those who are currently on PrEP (Table 9:
PrEP_Q2) are in Stage 4: PrEP Action. Stage 5: PrEP
Maintenance includes those who are currently prescribed PrEP
(Table 9: PrEP_Q2), adherent to their regimen (Table 9:
PrEP_Q14), and receiving quarterly HIV or STI testing (Table
9: PrEP_Q15).
Discussion
The ATN developed guidelines for harmonizing standard
measures for Demographics and Socioeconomic Characteristics,
Sexual Behavior and Risk, Substance Use and Abuse,
HIV-Negative Cascade, and HIV-Positive Cascade domains.
In addition, guidelines for additional measures commonly
collected among ATN studies were developed for Mental Health,
Social Support and Isolation, and PrEP Cascade domains. The
research goals of the ATN motivated many of the measures
included in these standard domains, especially the measures for
the HIV-Negative Cascade and HIV-Positive Cascade domains.
AC and working group members referred to existing surveys
and data collection tools, like YRBS, ASSIST, NHBS and
PROMIS, to develop the ATN harmonization guidelines. As
the ATN works to increase awareness of the HIV status and
access to health care for adolescents diagnosed with HIV in the
United States, the collection of selected key measures uniformly
across studies facilitates the characterization of participant
populations, comparisons between studies, and pooled analysis
of data from multiple studies.
Moving forward, the ATN should periodically evaluate the
utility of each of the harmonized measures currently being
collected across ATN studies and update these data
harmonization guidelines as needed. Some of the measures
currently included are relatively new and do not necessarily
have a robust evidence base supporting their validity and
reliability, especially in adolescents and young adults in the
United States. Therefore, it will be important for the ATN to
reassess these harmonized measures in the future. In addition,
gaps may be identified that warrant the inclusion of further
measures. For example, the current harmonized measures do
not consider stigma or cost-effectiveness. Related to
cost-effectiveness, the ATN Modeling Core recently formed a
working group to explore the feasibility of standardizing
cost-related measures collected in ATN studies or developing
guidelines for harmonizing cost-effectiveness analyses across
the network. Like the continuously evolving HIV epidemic, the
ATN-harmonized measures should evolve as well to ensure the
collection of data most relevant to defeating the HIV epidemic
among adolescents and young adults.
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